Its counterpart, the Phase III randomized PENELOPE trial (NCT01684878), was activated following promising Phase II data and studied pertuzumab in an enriched ovarian cancer patient population with low HER3 mRNA [56]. The gene discussed is ERBB3; the disease is ovarian cancer.